000			03749nam a22004335i 4500
001			978-3-540-72146-8
003			DE-He213
005			20161121230807.0
007			cr nn 008mamaa
008			100301s2008 gw | s |||| 0|eng d
020			_a9783540721468 _9978-3-540-72146-8
024	7		_a10.1007/978-3-540-72146-8 _2doi
050		4	_aQR355-502
072		7	_aMMFM _2bicssc
072		7	_aMED052000 _2bisacsh
082	0	4	_a616.9101 _223
245	1	0	_aHuman Antibody Therapeutics for Viral Disease _h[electronic resource] / _cedited by Scott K. Dessain.
264		1	_aBerlin, Heidelberg : _bSpringer Berlin Heidelberg, _c2008.
300			_aXII, 190 p. 18 illus., 7 illus. in color. _bonline resource.
336			_atext _btxt _2rdacontent
337			_acomputer _bc _2rdamedia
338			_aonline resource _bcr _2rdacarrier
347			_atext file _bPDF _2rda
490	1		_aCurrent Topics in Microbiology and Immunology, _x0070-217X ; _v317
505	0		_aTherapeutic Control of Hepatitis C Virus: The Role of Neutralizing Monoclonal Antibodies -- Antibodies for HIV Treatment and Prevention: Window of Opportunity? -- Human Monoclonal Antibody and Vaccine Approaches to Prevent Human Rabies -- Immunoprophylaxis of RSV Infection: Advancing from RSV-IGIV to Palivizumab and Motavizumab -- The Molecular Basis of Antibody Protection Against West Nile Virus -- Exploring the Native Human Antibody Repertoire to Create Antiviral Therapeutics.
520			_aThe articles in this volume have been selected to demonstrate the progress in the development of human antibody therapeutics for viral disease. Keck et al. review the nature of the immune response to the Hepatitis C virus (HCV) and the details of viral neutralization by antibodies, providing a conceptual model for the clinical use of HCV-specific antibodies. Huber et al. summarize the initial clinical experiences with antibody therapeutics for Human Immunodeficiency Virus that can be targeted to either the HIV virion or to host cell proteins. A discussion of the breadth immune strategies that is required to control human rabies is provided by Nagarajan et al., with a particular focus on India and other countries in which rabies is endemic. The development of pavilizumab for RSV prophylaxis is reviewed in Wu et al., in addition to results of antibody optimization studies that provide surprising insights and have broad general implications for anti-viral antibody engineering. Melhop and Diamond explicate the biology of West Nile Virus as a general model for flaviviruses, while using their cloned antibodies as a springboard to consider the mechanisms of WNV neutralization. The volume concludes with a description of methods to clone human antibodies in their native configurations, which access a class of antibodies that differ from those obtained by recombinant DNA or transgenic mouse methods. The articles in this volume are definitive and comprehensive reviews written by experts who have sought to define the principles of viral neutralization by human antibodies. They explore and anticipate the obstacles and opportunities that will be encountered as the power of human antibodies is harnessed to address the vast, un-met need for effective anti-viral therapeutics.
650		0	_aMedicine.
650		0	_aVirology.
650	1	4	_aBiomedicine.
650	2	4	_aVirology.
700	1		_aDessain, Scott K. _eeditor.
710	2		_aSpringerLink (Online service)
773	0		_tSpringer eBooks
776	0	8	_iPrinted edition: _z9783540721444
830		0	_aCurrent Topics in Microbiology and Immunology, _x0070-217X ; _v317
856	4	0	_uhttp://dx.doi.org/10.1007/978-3-540-72146-8
912			_aZDB-2-SBL
950			_aBiomedical and Life Sciences (Springer-11642)
999			_c504067 _d504067